💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Alfuzosin Hydrochloride

CHEMBL1723 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
425.9 g/mol
LogP
—
Phase
4

Relief of bladder outlet obstruction in benign prostatic hyperplasia is the therapeutic purpose of alfuzosin hydrochloride, the salt form of an alpha-1 adrenoceptor antagonist. Blockade of alpha-1 receptors relaxes smooth muscle in the prostate and bladder neck, widening the outflow tract so that urine flow improves and lower urinary tract symptoms diminish in men with the condition. The salt reproduces the pharmacology of the parent compound without altering its receptor selectivity or its site of action. Because the target is a vascular as well as a urinary receptor, the class is associated with blood-pressure-related effects. The compound is a small molecule, C19H28ClN5O4, of roughly 425.9 g/mol, approved and taken through the final phase of development.

The hydrochloride salt form of alfuzosin, an alpha-1 receptor antagonist used to relax smooth muscle in the prostate and bladder neck to relieve urinary obstruction caused by BPH. This formulation provides the same mechanism of action as the parent compound, improving urine flow and reducing bothersome lower urinary tract symptoms in men.

Molecular Weight

425.9000 g/mol

TPSA

112.00 Ų

Therapeutic Areas

Urology

Mechanism of Action

A selective alpha-1 adrenoceptor antagonist. Alfuzosin blocks alpha-1 receptors on prostatic and bladder-neck smooth muscle, relieving the dynamic component of bladder outlet obstruction in benign prostatic hyperplasia. Its extended-release formulation limits, but does not abolish, the vascular alpha-1 blockade responsible for dizziness and orthostatic hypotension.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

A selective alpha-1 adrenoceptor antagonist. Alfuzosin blocks alpha-1 receptors on prostatic and bladder-neck smooth muscle, relieving the dynamic component of bladder outlet obstruction in benign prostatic hyperplasia. Its extended-release formulation …

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H28ClN5O4

                    

                    
                    

                        
HBD / HBA

                        
3 / 8

                    

                    
                    

                        
Rotatable Bonds

                        
8

                    

                    
                    
                    

                        
Heavy Atoms

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
The hydrochloride salt form of alfuzosin, an alpha-1 receptor antagonist used to relax smooth muscle in the prostate and bladder neck to relieve urinary obstruction caused by BPH. This formulation provides the same mechanism of action as the parent compound, improving urine flow and reducing bothersome lower urinary tract symptoms in men.

                        

                    

                    

                    

                    
                    

                        
                        

                            
A selective alpha-1 adrenoceptor antagonist. Alfuzosin blocks alpha-1 receptors on prostatic and bladder-neck smooth muscle, relieving the dynamic component of bladder outlet obstruction in benign prostatic hyperplasia. Its extended-release formulation limits, but does not abolish, the vascular alpha-1 blockade responsible for dizziness and orthostatic hypotension.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Alfuzosin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1723.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71764.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.